Nanoparticle-mediated gene delivery to tumour neovasculature

被引：42

作者：

Reynolds, AR

Moghimi, SM

Hodivala-Dilke, K

机构：

[1] St Thomas Hosp, Richard Dimbledy Dept Canc Res, Canc Res UK, Cell Adhes & Dis Lab, London SE1 7EH, England

[2] Univ Brighton, Sch Pharm & Biomol Sci, Mol Targeting & Polymer Toxicol Grp, Brighton BN2 4GJ, E Sussex, England

来源：

TRENDS IN MOLECULAR MEDICINE | 2003年 / 9卷 / 01期

关键词：

D O I：

10.1016/S1471-4914(02)00004-7

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The alpha(v)beta(3) integrin is a potential pharmacological target for anti-angiogenic therapy. A recent report describes the use of alpha(v)beta(3)-targeted nanoparticles to deliver a gene to tumour vasculature selectively. This resulted in substantial tumour regression in several experimental mouse tumour models. Hence, this approach has great potential for the treatment of human cancer.

引用

页码：2 / 4

页数：3

共 17 条

[1] Antiangiogenic tumour therapy: will it work? [J].

Augustin, HG .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (06) :216-222

[2] REQUIREMENT OF VASCULAR INTEGRIN ALPHA(V)BETA(3) FOR ANGIOGENESIS [J].

BROOKS, PC ;

CLARK, RAF ;

CHERESH, DA .

SCIENCE, 1994, 264 (5158) :569-571

[3] INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS [J].

BROOKS, PC ;

MONTGOMERY, AMP ;

ROSENFELD, M ;

REISFELD, RA ;

HU, TH ;

KLIER, G ;

CHERESH, DA .

CELL, 1994, 79 (07) :1157-1164

[4] Involvement of integrins alpha(v)beta(3) and alpha(v)beta(5) in ocular neovascular diseases [J].

Friedlander, M ;

Theesfeld, CL ;

Sugita, M ;

Fruttiger, M ;

Thomas, MA ;

Chang, S ;

Cheresh, DA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (18) :9764-9769

[5]

Gutheil JC, 2000, CLIN CANCER RES, V6, P3056

[6] Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization [J].

Hammes, HP ;

Brownlee, M ;

Jonczyk, A ;

Sutter, A ;

Preissner, KT .

NATURE MEDICINE, 1996, 2 (05) :529-533

[7] Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J].

Hanahan, D ;

Folkman, J .

CELL, 1996, 86 (03) :353-364

[8] MUTATIONAL ACTIVATION OF C-RAF-1 AND DEFINITION OF THE MINIMAL TRANSFORMING SEQUENCE [J].

HEIDECKER, G ;

HULEIHEL, M ;

CLEVELAND, JL ;

KOLCH, W ;

BECK, TW ;

LLOYD, P ;

PAWSON, T ;

RAPP, UR .

MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (06) :2503-2512

[9] Tumor regression by targeted gene delivery to the neovasculature [J].

Hood, JD ;

Bednarski, M ;

Frausto, R ;

Guccione, S ;

Reisfeld, RA ;

Xiang, R ;

Cheresh, DA .

SCIENCE, 2002, 296 (5577) :2404-2407

[10] Therapeutic synthetic polymers: a game of Russian roulette? [J].

Hunter, AC ;

Moghimi, SM .

DRUG DISCOVERY TODAY, 2002, 7 (19) :998-1001

← 1 2 →